Cargando…

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzinke, Mark A., Fogel, Jessica M., Wang, Zhe, Piwowar-Manning, Estelle, Kofron, Ryan, Moser, Amber, Bhandari, Pradip, Gollings, Ryann, Bushman, Lane R., Weng, Lei, Halvas, Elias K., Mellors, John, Anderson, Peter L., Persaud, Deborah, Hendrix, Craig W., McCauley, Marybeth, Rinehart, Alex R., St Clair, Marty, Ford, Susan L., Rooney, James F., Adeyeye, Adeola, Chariyalertsak, Suwat, Mayer, Kenneth, Arduino, Roberto C., Cohen, Myron S., Grinsztejn, Beatriz, Hanscom, Brett, Landovitz, Raphael J., Eshleman, Susan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/
https://www.ncbi.nlm.nih.gov/pubmed/36995219
http://dx.doi.org/10.1128/aac.00053-23
_version_ 1785027590540492800
author Marzinke, Mark A.
Fogel, Jessica M.
Wang, Zhe
Piwowar-Manning, Estelle
Kofron, Ryan
Moser, Amber
Bhandari, Pradip
Gollings, Ryann
Bushman, Lane R.
Weng, Lei
Halvas, Elias K.
Mellors, John
Anderson, Peter L.
Persaud, Deborah
Hendrix, Craig W.
McCauley, Marybeth
Rinehart, Alex R.
St Clair, Marty
Ford, Susan L.
Rooney, James F.
Adeyeye, Adeola
Chariyalertsak, Suwat
Mayer, Kenneth
Arduino, Roberto C.
Cohen, Myron S.
Grinsztejn, Beatriz
Hanscom, Brett
Landovitz, Raphael J.
Eshleman, Susan H.
author_facet Marzinke, Mark A.
Fogel, Jessica M.
Wang, Zhe
Piwowar-Manning, Estelle
Kofron, Ryan
Moser, Amber
Bhandari, Pradip
Gollings, Ryann
Bushman, Lane R.
Weng, Lei
Halvas, Elias K.
Mellors, John
Anderson, Peter L.
Persaud, Deborah
Hendrix, Craig W.
McCauley, Marybeth
Rinehart, Alex R.
St Clair, Marty
Ford, Susan L.
Rooney, James F.
Adeyeye, Adeola
Chariyalertsak, Suwat
Mayer, Kenneth
Arduino, Roberto C.
Cohen, Myron S.
Grinsztejn, Beatriz
Hanscom, Brett
Landovitz, Raphael J.
Eshleman, Susan H.
author_sort Marzinke, Mark A.
collection PubMed
description HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm). This report describes 52 additional infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm). Retrospective testing included HIV testing, viral load testing, quantification of study drug concentrations, and drug resistance testing. The new CAB arm infections included 7 with CAB administration within 6 months of the first HIV-positive visit (2 with on-time injections, 3 with ≥1 delayed injection, and 2 who restarted CAB) and 11 with no recent CAB administration. Three cases had integrase strand transfer inhibitor (INSTI) resistance (2 with on-time injections and 1 who restarted CAB). Among 34 CAB infections analyzed to date, diagnosis delays and INSTI resistance were significantly more common in infections with CAB administration within 6 months of the first HIV-positive visit. This report further characterizes HIV infections in persons receiving CAB preexposure prophylaxis and helps define the impact of CAB on the detection of infection and the emergence of INSTI resistance.
format Online
Article
Text
id pubmed-10112247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-101122472023-04-19 Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H. Antimicrob Agents Chemother Antiviral Agents HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm). This report describes 52 additional infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm). Retrospective testing included HIV testing, viral load testing, quantification of study drug concentrations, and drug resistance testing. The new CAB arm infections included 7 with CAB administration within 6 months of the first HIV-positive visit (2 with on-time injections, 3 with ≥1 delayed injection, and 2 who restarted CAB) and 11 with no recent CAB administration. Three cases had integrase strand transfer inhibitor (INSTI) resistance (2 with on-time injections and 1 who restarted CAB). Among 34 CAB infections analyzed to date, diagnosis delays and INSTI resistance were significantly more common in infections with CAB administration within 6 months of the first HIV-positive visit. This report further characterizes HIV infections in persons receiving CAB preexposure prophylaxis and helps define the impact of CAB on the detection of infection and the emergence of INSTI resistance. American Society for Microbiology 2023-03-30 /pmc/articles/PMC10112247/ /pubmed/36995219 http://dx.doi.org/10.1128/aac.00053-23 Text en Copyright © 2023 Marzinke et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Marzinke, Mark A.
Fogel, Jessica M.
Wang, Zhe
Piwowar-Manning, Estelle
Kofron, Ryan
Moser, Amber
Bhandari, Pradip
Gollings, Ryann
Bushman, Lane R.
Weng, Lei
Halvas, Elias K.
Mellors, John
Anderson, Peter L.
Persaud, Deborah
Hendrix, Craig W.
McCauley, Marybeth
Rinehart, Alex R.
St Clair, Marty
Ford, Susan L.
Rooney, James F.
Adeyeye, Adeola
Chariyalertsak, Suwat
Mayer, Kenneth
Arduino, Roberto C.
Cohen, Myron S.
Grinsztejn, Beatriz
Hanscom, Brett
Landovitz, Raphael J.
Eshleman, Susan H.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title_full Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title_fullStr Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title_full_unstemmed Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title_short Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
title_sort extended analysis of hiv infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for hiv prevention: hptn 083
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/
https://www.ncbi.nlm.nih.gov/pubmed/36995219
http://dx.doi.org/10.1128/aac.00053-23
work_keys_str_mv AT marzinkemarka extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT fogeljessicam extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT wangzhe extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT piwowarmanningestelle extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT kofronryan extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT moseramber extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT bhandaripradip extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT gollingsryann extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT bushmanlaner extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT wenglei extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT halvaseliask extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT mellorsjohn extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT andersonpeterl extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT persauddeborah extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT hendrixcraigw extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT mccauleymarybeth extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT rinehartalexr extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT stclairmarty extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT fordsusanl extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT rooneyjamesf extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT adeyeyeadeola extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT chariyalertsaksuwat extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT mayerkenneth extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT arduinorobertoc extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT cohenmyrons extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT grinsztejnbeatriz extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT hanscombrett extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT landovitzraphaelj extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083
AT eshlemansusanh extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083